Dyadic International Inc. (DYAI)
DYAI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1213809/000149315226012672/0001493152-26-012672-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DYAI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001213809 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.1M |
| Net income | -$7.4M |
| Operating income | -$7.2M |
| Net margin | -238.3% |
| Operating margin | -232.8% |
| Revenue growth | -11.6% |
| Cash | $4.6M |
| Total assets | $9.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors include, but are not limited to (i) our history of net losses, and management's related conclusion that there is substantial doubt about our ability to continue as a going concern for 12 months following November 13, 2026, the date the financial statements are issued;" | 10-Q 2026-11-13 |
| Cash and burn | $1.4M cash; operating cash flow -$1.9M a quarter. | Report 2026-06-30 |
| Shares outstanding | 40,091,203 (2026-11-12); 36,187,798 a year earlier; 28,811,061 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-08-13 |
| Exchange deficiency notices, 12 months | 4 (8-K item 3.01) | 8-K 2026-09-25 |
| Auditor | Crowe LLP, Livingston, New Jersey, United States | PCAOB Form AP 2026-04-02 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $125K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $961K | -$2.1M | -$1.8M | $1.4M | No debt tags | $3.8M | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $1.1M | -$2.0M | -$2.0M | $4.2M | No debt tags | $3.8M | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $566K | -$1.6M | -$1.8M | $4.6M | No debt tags | $3.1M | 10-K 2026-03-25 |
| Q3 2025 2025-09-30 | $1.2M | -$2.0M | -$1.9M | $5.8M | No debt tags | $3.3M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $967K | -$1.8M | -$130K | $2.1M | No debt tags | $4.1M | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $394K | -$2.0M | -$1.9M | $5.1M | No debt tags | $3.6M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $817K | -$1.6M | -$696K | $6.5M | No debt tags | $3.5M | 10-K 2026-03-25 |
| Q3 2024 2024-09-30 | $2.0M | -$203K | -$201K | $5.9M | No debt tags | $3.4M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-09-18 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-06-18 |
Source: SEC EDGAR submissions feed, 542 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.9% |
| 1 month | -23.3% |
| 3 months | -57.1% |
| Year to date | -64.9% |
| 1 year | -63.7% |
| From 52-week high | -77.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JSPR | Jasper Therapeutics Inc. | $11.77 | -13.96% | $13.1M |
| PASG | Passage Bio Inc. | $4.13 | -2.82% | $13.3M |
| ATYR | aTyr Pharma Inc. | $5.24 | -14.17% | $13.4M |
| BCDA | BioCardia Inc. | $0.7901 | -4.92% | $12.0M |
| PLUR | Pluri Inc. | $1.04 | -0.95% | $15.0M |
| SCLX | Scilex Holding Company | $1.25 | -12.59% | $10.6M |
| ABOS | Acumen Pharmaceuticals Inc. | $0.2160 | +0.93% | $15.6M |
| ALGS | Aligos Therapeutics Inc. | $1.66 | -20.95% | $10.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier